IRIS Institutional Research Information System - AIR Archivio Istituzionale della Ricerca

TARAMASSO, LUCIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.692
AS - Asia 4.107
EU - Europa 3.566
Continente sconosciuto - Info sul continente non disponibili 563
SA - Sud America 500
AF - Africa 122
OC - Oceania 27
Totale 13.577
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.291
SG - Singapore 1.267
IT - Italia 1.097
CN - Cina 1.032
GB - Regno Unito 679
VN - Vietnam 475
BD - Bangladesh 401
BR - Brasile 388
HK - Hong Kong 364
DE - Germania 321
RU - Federazione Russa 318
CA - Canada 317
SE - Svezia 232
FR - Francia 224
IE - Irlanda 191
IN - India 178
NL - Olanda 130
ID - Indonesia 122
FI - Finlandia 81
ES - Italia 54
JP - Giappone 43
UA - Ucraina 42
DK - Danimarca 41
AR - Argentina 38
KR - Corea 34
CI - Costa d'Avorio 33
ZA - Sudafrica 33
TR - Turchia 29
AT - Austria 27
AU - Australia 27
MX - Messico 27
BE - Belgio 26
PL - Polonia 26
IQ - Iraq 24
PH - Filippine 16
EC - Ecuador 15
TW - Taiwan 15
PK - Pakistan 14
CH - Svizzera 13
CR - Costa Rica 13
CO - Colombia 12
CL - Cile 11
PE - Perù 11
PY - Paraguay 11
JM - Giamaica 10
UZ - Uzbekistan 10
GR - Grecia 9
MY - Malesia 9
SA - Arabia Saudita 9
ET - Etiopia 8
KE - Kenya 7
AZ - Azerbaigian 6
CZ - Repubblica Ceca 6
KZ - Kazakistan 6
MA - Marocco 6
NP - Nepal 6
RO - Romania 6
SV - El Salvador 6
TN - Tunisia 6
UY - Uruguay 6
JO - Giordania 5
LT - Lituania 5
LU - Lussemburgo 5
PS - Palestinian Territory 5
TH - Thailandia 5
VE - Venezuela 5
BG - Bulgaria 4
BY - Bielorussia 4
HN - Honduras 4
IL - Israele 4
NG - Nigeria 4
NO - Norvegia 4
AL - Albania 3
BH - Bahrain 3
DO - Repubblica Dominicana 3
EG - Egitto 3
GE - Georgia 3
IR - Iran 3
LA - Repubblica Popolare Democratica del Laos 3
NI - Nicaragua 3
OM - Oman 3
PA - Panama 3
PR - Porto Rico 3
RS - Serbia 3
SI - Slovenia 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AE - Emirati Arabi Uniti 2
AM - Armenia 2
BA - Bosnia-Erzegovina 2
BB - Barbados 2
BO - Bolivia 2
DZ - Algeria 2
EE - Estonia 2
GH - Ghana 2
GT - Guatemala 2
HR - Croazia 2
HU - Ungheria 2
LB - Libano 2
LY - Libia 2
PT - Portogallo 2
Totale 12.982
Salva come PNG Salva come JPEG
Città #
Singapore 727
Southend 530
Ashburn 507
San Jose 350
Chandler 342
Hong Kong 291
Dallas 289
Milan 246
Dublin 189
Beijing 180
Council Bluffs 175
Fairfield 169
Princeton 161
Santa Clara 152
Frankfurt am Main 150
Toronto 142
Ho Chi Minh City 138
Los Angeles 138
Hanoi 113
Wilmington 100
Seattle 92
Rome 90
Jakarta 89
Buffalo 88
Lauterbourg 88
New York 88
Bengaluru 82
Houston 78
Ann Arbor 75
Ottawa 72
Woodbridge 71
Helsinki 67
Boardman 66
Des Moines 66
Hanover 63
Hefei 63
Cambridge 55
Central District 51
Turin 51
Guangzhou 48
Redwood City 47
Moscow 42
Phoenix 37
Naples 35
Abidjan 33
São Paulo 33
Shanghai 30
Chicago 28
Seoul 27
Da Nang 25
Montreal 25
Bologna 24
Tokyo 24
London 23
Cangzhou 22
Columbus 22
Genoa 22
Nanjing 22
Shenzhen 22
Amsterdam 21
Palermo 21
Nuremberg 20
Vienna 20
San Diego 19
Belo Horizonte 18
Madrid 18
City of London 17
Dearborn 17
Atlanta 16
The Dalles 16
Baghdad 15
Jinan 15
Redondo Beach 15
Dong Ket 14
Florence 14
Tianjin 14
Warsaw 14
Washington 14
Haiphong 13
Hangzhou 13
Mumbai 13
Rio de Janeiro 13
Berlin 12
Biên Hòa 12
Boston 12
Brussels 12
Falls Church 12
Munich 12
San Francisco 12
Chennai 11
Düsseldorf 11
Kent 11
Brooklyn 10
Eau Claire 10
Fuzhou 10
Mexico City 10
Bracknell 9
Catania 9
Charlotte 9
Manchester 9
Totale 7.638
Salva come PNG Salva come JPEG
Nome #
Aumento del peso nelle persone che vivono con infezione da HIV: ritorno al benessere o effetto indesiderato della terapia antiretrovirale? = Weight gain in people living with HIV infection : return to health or adverse event of antiretroviral therapy? 447
Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study 383
Positioning of darunavir/cobicistat-containing antiretroviral regimens in real life: Results from a large multicentre observational prospective cohort (SCOLTA) 327
Duration of quarantine in hospitalized patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: a question needing an answer 267
The impact of DAA-mediated HCV eradication on CD4+ and CD8+ T lymphocyte trajectories in HIV/HCV coinfected patients: Data from the ICONA Foundation Cohort 227
Risk of clinical events in virologically suppressed people with HIV switching to a two-drug regimen vs. remaining on a three-drug regimen: a target trial emulation 224
Integrase inhibitors use and CMV infection predict immune recovery in peolple living with HIV starting first-line therapy 220
HIV-associated neurocognitive impairment in the modern ART era : are we close to discovering reliable biomarkers in the setting of virological suppression? 218
Improvement of lipid profile after switching from efavirenz or ritonavir-boosted protease inhibitors to rilpivirine or once-daily integrase inhibitors : results from a large observational cohort study (SCOLTA) 216
Effectiveness of a project to prevent HIV vertical transmission in the Republic of Congo 215
Pharmacokinetics of lopinavir determined with an ELISA test in youths with perinatally acquired HIV 210
Pillars of long-term antiretroviral therapy success 201
Trend of estimated glomerular filtration rate during ombistasvir/paritaprevir/ritonavir plus dasabuvir± ribavirin in HIV/HCV co-infected patients 194
Treatment simplification to atazanavir/ritonavir plus lamivudine versus maintenance of atazanavir/ritonavir plus two nucleoside reverse transcriptase inhibitors in virologically-suppressed HIV-1-infected patients : 48-weeks results from a randomized trial (ATLAS-M) 193
Onychomadesis in a male patient with secondary syphilis 188
Effectiveness of dolutegravir-based vs boosted darunavir-based first-line 3-drug regimens in people with HIV with advanced dimalsease: a trial emulation 184
CD8+CD28-CD127loCD39+regulatory T-cell expansion: A new possible pathogenic mechanism for HIV infection? 182
Metabolic syndrome and body weight in people living with HIV infection: analysis of differences observed in three different cohort studies over a decade 181
HIV-1 RNA quantification in CRF02_AG HIV-1 infection: too easy to make mistakes 170
Weight Gain : A Possible Side Effect of All Antiretrovirals 168
Lipid profile changings after switching from rilpivirine/tenofovir disoproxil fumarate/ emtricitabine to rilpivirine/tenofovir alafenamide/emtricitabine: Different effects in patients with or without baseline hypercholesterolemia 168
Pneumocystis jirovecii pneumonia in HIV-negative patients, a frequently overlooked problem. A case series from a large Italian center 163
Long-term outcome of dolutegravir-containing regimens according to sex: data from the ICONA Study 162
Proportion of newly diagnosed persons with HIV with HIV-RNA greater than/equal to 500,000 copies/mL in 2018-2023 in Italy: data from the ICONA Foundation Cohort Study 162
First-line antiretroviral therapy with efavirenz plus tenofovir disiproxil fumarate/emtricitabine or rilpivirine plus tenofovir disiproxil fumarate/emtricitabine: a durability comparison 161
Epidemiology, species distribution, antifungal susceptibility and outcome of nosocomial candidemia in a tertiary care hospital in Italy 154
Comparable gut mucosal breakdown and microbial translocation in severe COVID-19 with and without HIV infection 152
Increasing use and accessibility of anti parasitic drugs for migrants with neglected diseases at a time of migratory emergency 151
Maintenance of viral suppression after optimization therapy from etravirine plus raltegravir to rilpivirine plus dolutegravir in HIV-1-infected patients 146
Incidence and risk factors for liver enzyme elevation among naive HIV-1-infected patients receiving ART in the ICONA cohort 145
Switch from unboosted protease inhibitor to a single-tablet regimen containing rilpivirine improves cholesterol and triglycerides 144
Bedaquiline : a new hope for shorter and better anti-tuberculosis regimens 143
Time to change the single-centre approach to management of patients with tuberculosis : a novel network platform with automatic data import and data sharing 142
Bloodstream infections in HIV-infected patients 142
Switching to Integrase Inhibitors Unlinked to Weight Increase in Perinatally HIV-Infected Young Adults and Adolescents : A 10-Year Observational Study 142
Effectiveness of first-line lamivudine/dolutegravir antiretroviral therapy in persons with HIV: real-life data from the ICONA Foundation cohort 141
Predictors of weight gain in patients treated with dolutegravir 141
HCV elimination plan leads to significant benefits in managing liver-related diseases and hospital interventions : a regional simulation 140
Bloodstream infections in patients living with HIV in the modern cART era 140
Missed opportunities to prevent mother-to-child transmission of HIV in Italy 139
Question and answers on long-acting therapy with cabotegravir and rilpivirine in people with HIV 138
Management of ventilator-associated pneumonia: epidemiology, diagnosis and antimicrobial therapy 138
Case report : management and HBV sequencing in a patient co-infected with HBV and HIV failing tenofovir 138
Atazanavir/ritonavir with lamivudine as maintenance therapy in virologically suppressed HIV-infected patients: 96 week outcomes of a randomized trial 136
Ibalizumab and fostemsavir in the management of heavily pre-treated HIV-infected patients 135
Missed opportunities in tb clinical practice: How to bend the curve? A medical, social, economic and ethical point of view 134
Ligurian Vaccination in HIV Program (LIV in HIV): the experience of Genoa metropolitan area 133
Starting HIV therapy in patients with mitochondrial disease 133
Duration of isolation and precautions in immunocompromised patients with COVID-19 132
Will new antimicrobials overcome resistance among Gram-negatives? 131
HIV infection among adolescents and young adults in Italy: epidemiology, viro-immunological and treatment outcomes 129
The switch from TDF to TAF determines weight gain in patients on rilpivirine-based regimen 123
Attributable mortality of candidemia - Results from the ECMM Candida III multinational European Observational Cohort Study 122
Chemotherapy Mass Campaigns and Migratory Flows : An Unexpected Connection 122
Lipid profile changings after switching from rilpivirine/tenofovir disoproxil fumarate/emtricitabine to rilpivirine/tenofovir alafenamide/emtricitabine: different effects in different patients populations : results from a large observational study 120
Role of raltegravir in patients co-infected with HIV and HCV in the era of direct antiviral agents 119
Immunonutrition in human immunodeficiency virus infection : which populations to target? 119
Short Communication : Tenofovir Disoproxil Fumarate/Emtricitabine Fits for All as Appropriate HIV-1 Pre-Exposure Prophylaxis? 118
Control of the HIV-1 DNA reservoir is associated in vivo and in vitro with NKp46/NKp30 (CD335 CD337) inducibility and interferon gamma production by transcriptionally unique NK cells 118
Factors associated with hospital admission for COVID-19 in HIV patients 118
Pregnancy and neonatal outcomes among a cohort of HIV-infected women in a large Italian teaching hospital : a 30-year retrospective study 117
SARS-CoV-2 mRNA vaccination and short-term changes in viral load and CD4/CD8 T-cell counts in people living with HIV 116
Use of quantitative ultrasound as bone mineral density evaluation in an Italian female population living with HIV: A real-life experience 116
How relevant is the HIV low level viremia and how is its management changing in the era of modern ART? A large cohort analysis 116
Incident diabetes in course of antiretroviral therapy 115
Durability of Dolutegravir-Based Regimens: A 5-Year Prospective Observational Study 114
Increasing prevalence of genitourinary schistosomiasis in Europe in the Migrant Era : Neglected no more? 113
Tigecycline use in hospital and its potential role in infection control 111
Hypertensive versus HIV-infected patients : Who has the greatest target organ damage? Comparison of carotid plaque prevalence, intima media thickness and renal resistive index in the two groups of patients 110
Real-life safety of Emtricitabine/Tenofovir Alafenamide/Bictegravir 105
Epidemiological and clinical features of hepatitis delta in HBsAg-positive patients by HIV status 105
Bloodstream infections in patients living with HIV infection in the recent cART era: did something change? 101
Hepatitis C virus direct acting antivirals impact on renal function in the first 4 weeks of treatment 100
Statins and Aspirin use in HIV-infected people: gap between European AIDS Clinical Society guidelines and clinical practice : the results from HIV-HY study 100
Is it still worthwhile to perform quarterly cd4+ t lymphocyte cell counts on hiv-1 infected stable patients? 98
Is it time to re-think the use of etravirine in patients with available genotypic resistance test? 96
Reducing CD4+ lymphocyte cell monitoring in HIV-1 stable patients: a forecast of the cost saving 96
Evidence gaps on weight gain in people living with HIV: a scoping review to define a research agenda 93
Immunological profile of an infant treated with integrase inhibitor from the neonatal period 92
Treatment of hepatitis C virus genotype 4 in the DAA era 85
Lipid profile improvement in virologically suppressed hiv-1-infected patients switched to dolutegravir/ abacavir/lamivudine : Data from the SCOLTA project 85
How has the cost of antiretroviral therapy changed over the years? A database analysis in Italy 83
Rationale for an association between PD1 checkpoint inhibition and therapeutic vaccination against HIV 83
L’insufficienza tricuspidale funzionale: un’entità clinica di crescente importanza 80
Predictors of incomplete viral response and virologic failure in patients with acute and early HIV infection. Results of Italian Network of ACuTe HIV InfectiON (INACTION) cohort 80
Raltegravir-based therapy in a cohort of HIV/HCV co-infected individuals 78
Co-administration of tenofovir plus protease inhibitor based antiretroviral therapy during sofosbuvir/ledipasvir treatment for HCV infection : Much Ado About Nothing? 77
Which patients have greatest need for elvitegravir/cobicistat/ emtricitabine/tenofovirDF-based therapy? 72
Time trend in hypertension prevalence, awareness, treatment, and control in a contemporary cohort of HIV-infected patients : The HIV and Hypertension Study 72
Pineal Germinoma in a Child with Interferon-γ Receptor 1 Deficiency : Case Report and Literature Review 71
Patient-reported outcomes and low-level residual HIV-RNA in adolescents perinatally infected with HIV-1 after switching to one-pill fixed-dose regimen 68
Therapeutic management of chronic hepatitis B in clinical Practice: a region-wide survey 67
Brief Report: New HIV Diagnoses in PrEP-Experienced and PrEP-Naive Persons in the ICONA Cohort 66
Lamivudine resistance mutations in European patients with hepatitis B and patients co-infected with HIV and hepatitis B 64
Role of [18F]Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography for Diagnosis and Treatment of Sarcoidosis in an HIV-2-Infected Patient 64
Successful recovery of associated interstitial nephritis and focal segmental glomerulosclerosis in patients with HCV and HIV treated with sofosbuvir and daclatasvir and revision of literature 61
Successful antiretroviral therapy by using unusual antiretroviral combinations in heavily pre-treated patients: two case reports 57
Did the COVID-19 pandemic shift the landscape of late HIV diagnosis? 40
Selected comorbidities and the probability of ART switch in PWH with undetectable HIV-RNA: a retrospective analysis in Italy 33
A machine learning-derived cardiovascular risk score in people with HIV: the ML-ICONA score 28
Totale 13.577
Salva come PNG Salva come JPEG
Categoria #
all - tutte 42.465
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 42.465
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.028 0 59 69 85 55 32 61 145 188 93 30 211
2022/20231.237 154 132 83 151 119 235 37 62 110 27 105 22
2023/2024851 25 77 28 52 174 96 47 59 24 40 108 121
2024/20252.135 66 193 64 188 251 104 61 204 153 178 217 456
2025/20265.717 477 386 566 480 434 321 672 253 571 486 585 486
2026/2027518 403 115 0 0 0 0 0 0 0 0 0 0
Totale 13.577